Could your own immune cells fight ovarian cancer? tiny trial aims to find out
NCT ID NCT07651124
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether a patient's own tumor-fighting immune cells (called TILs) can be safely used to treat recurrent ovarian cancer. Researchers take a sample of the tumor, grow the immune cells in a lab, and then inject them back into the patient. Only 6 people will take part, and the main goal is to check for side effects, not yet to see if it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
autologous tumor-infiltrating lymphocytes (TILs)
What this could lead to
If it works, this could point toward a new treatment option for recurrent ovarian cancer using a patient's own immune cells.
What could go wrong
This is a very early safety trial with only 6 participants, so it is too small to prove effectiveness. The treatment involves chemotherapy and high-dose IL-2, which can cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bundang CHA Medical Center
RECRUITINGGyeonggi-do, Bundang-gu, 13520, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••